Development of the model for the non-conformance correction and prevention process in clinical trials

Authors

DOI:

https://doi.org/10.24959/cphj.18.1474

Keywords:

clinical trial quality management, corrective action, preventive action, risk management

Abstract

The use of the CAPA-planning method to correct and prevent the risks emergence when organizing and conducting clinical trials (CT) of new drugs can close the cycle of actions between identifying the problem and the action to solve it. Our preliminary analysis of regulatory documentation showed the lack of unified harmonized requirements for this type of processes when organizing and conducting CT.

Aim. To develop the algorithm for using the CAPA-planning method during the process of non-conformance correction and prevention when organizing and conducting CT.

Materials and methods. The practical approaches used to develop CAPA-plans were assessed. The algorithm for the process of non-conformance correction and prevention was created. Methods of meta-analysis, abstraction, synthesis and generalization were used in this work.

Results. Our analysis of the experience of using organizational structures for designing CAPA-plans has shown that the most convenient and effective for work is the form of drafting and execution of the CAPA-plan in the form of a consolidated table of all non-conformances identified. Quality management of CT using the CAPA-planning method is a multi-stage process that begins with non-conformance identification during the inspection or control and ends with the documented correction and prevention of all non-conformances identified.

Conclusions. A review of the existing methods for organizing CAPA-plans indicates the absence of the general principles for their drafting, registration and work with them. The algorithm for the interfunctional process for non-conformance correction and prevention with the help of the CAPA-planning method has been developed.

Author Biographies

T. Yu. Kolodyezna, National University of Pharmacy

postgraduate student of the Department of Clinical Pharmacology and Clinical Pharmacy

V. Ye. Dobrova, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), professor of the Department of Clinical Pharmacology and Clinical Pharmacy

K. O. Zupanets, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy

O. O. Liapunova, National University of Pharmacy

Candidate of Pharmacy (PhD), associate professor of the Industrial Pharmacy Department

References

Meeker-O’Connell, A., Sam, L. M., Bergamo, N., & Little, J. A. (2016). TransCelerate’s Clinical Quality Management System. Therapeutic Innovation & Regulatory Science, 50(4), 397–413. https://doi.org/10.1177/2168479016651300

Kolodyezna, T., Zupanets, K., Dobrova, V. (2018). Evaluation of opportunities for the use of modern methods for correction and prevention of risks in the quality control of clinical trials. ScienceRise: Pharmaceutical Science, 5 (15), 10–16.

Meeker-O’Connell, A., Glessner, C., Behm, M., Mulinde, J., Roach, N., Sweeney, F., … Landray, M. J. (2016). Enhancing clinical evidence by proactively building quality into clinical trials. Clinical Trials: Journal of the Society for Clinical Trials, 13(4), 439–444. https://doi.org/10.1177/1740774516643491

Zupanets, E. A., & Dobrova, V. Y. (2016). The analysis of specialists’ opinion on the implementation of concept of risk management in clinical trials of drugs. Zaporozhye Medical Journal, 3, 93–98. https://doi.org/10.14739/2310-1210.2016.3.77004

Meeker-O’Connell, A., Borda, M. M., Little, J. A., & Sam, L. M. (2015). Enhancing Quality and Efficiency in Clinical Development Through a Clinical QMS Conceptual Framework. Therapeutic Innovation & Regulatory Science, 49(5), 615–622. https://doi.org/10.1177/2168479015596018

Callery-D’Amico, S., Sam, L. M., Grey, T. H., & Greenwood, D. J. (2016). TransCelerate’s Clinical Quality Management System. Therapeutic Innovation & Regulatory Science, 50(5), 530–535. https://doi.org/10.1177/2168479016657129

Guideline ICH GCP E6 (R2) Step 5 Addendum. (2016). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf

ICH Q10 Nastanova «Likarski zasobi. Farmatsevtichna sistema yakosti». (2011). Available at: http://www.gmpua.com/World/Ukraine/nastanova42432011.pdf

ICH GCP Nastanova «Likarski zasobi. Nalezhna klinichna praktika». (2009). Available at: http://www.gmpua.com/World/Ukraine/nastanova42702008.pdf

Standard ISO 9001:2015. (2015). Available at: http://pqm-online.com/assets/files/pubs/translations/std/iso-9001-2015-(rus).pdf

Official web-site of research center at Loughborough University. (n.d.). Available at: https://www.lboro.ac.uk/research/

Mehra, M., Kurpanek, K., Petrizzo, M., Brenner, S., McCracken, Y., Katz, T., & Gurian, M. (2014). The Life Cycle and Management of Protocol Deviations. Therapeutic Innovation & Regulatory Science, 48(6), 762–777. https://doi.org/10.1177/2168479014530119

Official web-site of research center at Cleveland Medical Center University Hospitals. (n.d.). Available at: http://www.uhhospitals.org/clinical-research/clinical-research-center-core-offices/research-compliance-education-and-outreach

Official web-site of research center at USF Health CRC. (n.d.). Available at: https://health.usf.edu/medicine/research/ocr/morsani-clinical-research

Official web-site of research center at UW Institute for Clinical and Translational Research. (n.d.). Available at: https://ictr.wisc.edu/

Downloads

Published

2018-11-29

Issue

Section

Clinical trials